RecruitingPhase 1NCT04960579

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Sponsor

Poseida Therapeutics, Inc.

Enrollment

275 participants

Start Date

May 5, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of cell therapy called P-BCMA-ALLO1 — a treatment made from donated immune cells engineered to attack multiple myeloma (a type of blood cancer). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with active multiple myeloma that can be measured - Your myeloma has come back or stopped responding to treatment, and you have previously tried at least three types of therapy (a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 therapy) - You are willing to use reliable birth control during and for at least one year after treatment - If you had a stem cell transplant, it was at least 90 days ago - Your vital organs (heart, liver, kidneys, lungs) are functioning adequately **You may NOT be eligible if...** - You have certain serious infections (like active HIV or hepatitis B/C) - You have significant organ damage - You are pregnant or breastfeeding - You are not willing or able to use birth control Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALP-BCMA-ALLO1 CAR-T cells

Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy

DRUGRimiducid

Safety switch activator

DRUGMethotrexate

Anti-metabolite

Locations(23)

City of Hope

Goodyear, Arizona, United States

University of California San Diego

San Diego, California, United States

University of California San Francisco

San Francisco, California, United States

Emory University

Atlanta, Georgia, United States

Blood Marrow and Transplant Group of Georgia

Atlanta, Georgia, United States

City of Hope

Chicago, Illinois, United States

Advocate Aurora Health

Park Ridge, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

Wayne State - Karmanos Cancer Institute

Detroit, Michigan, United States

Hackensack Meridian Health

Hackensack, New Jersey, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Mount Sinai

New York, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

University of Cincinnati

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Oklahoma, Health Sciences Center

Oklahoma City, Oklahoma, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Sarah Cannon Research Institute - St. David's South Austin Medical Center

Austin, Texas, United States

Houston Methodist Research Institute

Houston, Texas, United States

Sarah Cannon Research Institute - Methodist Healthcare

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04960579

Related Trials

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575273 locations